Myotonia May Amplify Muscle Damage in Myotonic Dystrophy Type 1, New Study Reveals
核心洞察
A University of Rochester study published in Nature Communications finds that myotonia actively worsens muscle damage in DM1 rather than merely reflecting disease severity.
Genetically correcting the chloride channel (搜索) in a DM1 mouse model eliminated myotonia and led to healthier muscles, greater force generation, and broad improvements in gene expression.
The findings suggest myotonia acts as a "volume knob" on the disease, amplifying damage even when the underlying toxic RNA remains present.
A new study from the University of Rochester Medicine (搜索), published in Nature Communications, challenges long-held assumptions about myotonic dystrophy type 1 (搜索) (DM1) by demonstrating that muscle stiffness—long considered a secondary symptom—may actively drive the progressive muscle degeneration that defines the disease.
"Our findings suggest that myotonia isn't simply an uncomfortable symptom people experience," said John Lueck, PhD, associate professor of Pharmacology and Physiology at University of Rochester Medicine (搜索) and senior author of the study. "It appears to amplify the harmful effects of the disease in muscles. When we eliminated myotonia in our mouse model, we didn't just improve muscle relaxation; we saw healthier muscles overall."
The Toxic RNA Mechanism
DM1, the most common form of adult muscular dystrophy, is an inherited disorder characterized by progressive muscle weakness, muscle wasting, slow relaxation after muscle contraction, heart rhythm abnormalities, cataracts, and excessive daytime sleepiness. The disease originates from an abnormal expansion of repeated DNA segments in the DMPK (搜索) gene, which produces a toxic RNA molecule that traps proteins essential for correct genetic processing. This disruption leads to improper splicing of hundreds to thousands of genes, yielding abnormal protein versions throughout the body.
Decades of research led by URochester Medicine neurologist Charles Thornton, MD, a co-author of the study, helped establish how this toxic RNA disrupts normal RNA splicing and drives disease pathology. Among the most critically affected genes is one encoding a chloride channel (搜索) that enables muscles to relax after contraction. When disrupted, muscles become electrically overactive, producing the hallmark delayed relaxation known as myotonia.
Isolating Myotonia's Contribution
While most research has concentrated on eliminating the toxic RNA itself—with several RNA-targeted therapies advancing toward clinical use—Lueck and colleagues sought to answer a different question: once myotonia develops, does it merely reflect the disease, or does it actively worsen muscle damage?
Previous work from the URochester Medicine team had provided early clues. They found that when myotonia occurred alongside another splicing defect affecting calcium channels, muscle disease became dramatically worse in mice, and calcium channel-blocking drugs reversed many of those effects. That finding suggested muscle hyperexcitability might directly contribute to muscle degeneration.
"We've spent years trying to understand which of the many splicing changes actually matter most," Lueck said. "This study allowed us to isolate one of those changes and ask what happens when you permanently remove myotonia while leaving the underlying disease process in place."
Myotonia as a "Volume Knob"
To answer this question, the researchers genetically corrected a single critical portion of the chloride channel (搜索) gene in a mouse model of DM1. The results exceeded expectations: the mice not only lost muscle stiffness but also generated greater muscle force, showed healthier muscle tissue under the microscope, and experienced broad improvements in abnormal gene expression and RNA splicing.
"The toxic RNA is still present," Lueck noted. "But myotonia appears to turn up the damage happening in muscles. When we turned myotonia down, many aspects of muscle health improved, even though we hadn't corrected the original genetic mutation." The team describes myotonia as functioning like a "volume knob" on the disease—amplifying the harmful effects driven by the toxic RNA.
Therapeutic Implications
The findings carry significant implications for DM1 treatment strategies. Several experimental therapies currently in development aim to eliminate the toxic RNA, and researchers have long used improvements in myotonia as an early efficacy signal because the chloride channel (搜索) is particularly sensitive to correction. The new study suggests that reducing myotonia may itself contribute meaningfully to improved muscle health—potentially slowing or reducing muscle damage beyond simply relieving stiffness.
Additionally, existing medications that reduce myotonia, including mexiletine and ranolazine, may deserve renewed attention. Although these drugs can improve muscle stiffness, side effects often limit their long-term use, and many people with DM1 never receive them.
"If we can develop safer, better-tolerated myotonia drugs, they could become an important complement to RNA-based therapies—or provide meaningful benefit for patients who don't have access to those advanced treatments," said Lueck.
The study was funded with support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the Myotonic Dystrophy Foundation, the National Institute of Dental and Craniofacial Research, the National Institute of General Medical Sciences, and the German Research Foundation. Additional co-authors include Matthew T. Sipple, Sakura A. Hamazaki, Lily A. Cisco, Christina S. Heil, and Katherine M. Lupia with URochester Medicine, Vanessa Todorow with Yale University, and Peter Meinke with the Friedrich-Baur-Institute in Germany.